Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Selecting Candidates for NHI Re-pricing
January 16, 2006
- Flu Season Begins Six Weeks Early: Korosho
January 16, 2006
- NDA Filed for Anti-RA Adalimumab: Eisai, Abbott Japan
January 16, 2006
- First Anti-cancer Pharmacotherapy Specialists to Be Certified by the JSMO in April
January 16, 2006
- Astellas' Hyponatremia Treatment Vaprisol Approved in the US
January 16, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 16, 2006
- Novartis Files NDA for Additional Indication of Glivec
January 16, 2006
- SURVEY 3 articles
January 16, 2006
- Peg-Intron, Rebetol Combination Granted Additional Indication
January 16, 2006
- Aricept Orodispersible Tablet Completes MRP in 12 EU Countries
January 16, 2006
- REGULATORY NEWS IN BRIEF
January 16, 2006
- Nippon Shinyaku Licenses CML Treatment NS-187 to INNOVIVE of the US
January 16, 2006
- BUSINESS NEWS IN BRIEF
January 16, 2006
- SELF-MEDICATION NEWS IN BRIEF
January 16, 2006
- 3 Associations Draft Proposal on Med. Device Safety Management
January 9, 2006
- STATISTICS
January 9, 2006
- ACCJ Calls For Improvement in Review of Medical Devices
January 9, 2006
- ＜New Year's Greeting＞PhRMA to Work to More Quickly Bring Innovative Drugs to Patients
January 9, 2006
- MEDICAL DEVICE NEWS IN BRIEF
January 9, 2006
- Surprise Free Forecasts For 2006
January 9, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…